The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.
1don MSN
Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...
Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...
Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform. The treatments will each cost $ ...
BofA keeps an Underperform rating on Hims & Hers with a $22 price target after the company indicated it is adding a branded version of Eli ...
weight loss drug Zepbound is no longer in shortage. Hims & Hers (NYSE:HIMS) markets compounded versions of rival Novo Nordisk’s (NVO) weight loss therapy semaglutide at a sharp discount to the ...
Compounding pharmacies and telehealth firms such as Hims & Hers had been allowed to produce hundreds of thousands of doses of copies of weight-loss drugs Wegovy and Eli Lilly’s Zepbound ...
though still higher than the compounded versions Hims had been selling. Eli Lilly is following suit with a similar pricing strategy for Zepbound. With major insurers expanding coverage and direct ...
Hims & Hers is a newfangled telehealth company that ... Then, on 5/20/24, HIMS metaphorically pushed harder on the launch button. It announced it would make GLP-1 injections available to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback